Tareq Abadl: The Hidden Danger in a Blood Bag – When a Unit Looks ‘Wrong’
Tareq Abadl, Medical Lab Specialist, shared a post onย LinkedIn:
“The Hidden Danger in a Blood Bag: When a Unit Looks ‘Wrong’
Did you know that if a blood bag contains visible clots or fibrin strands, it should not be transfused?
Many people think transfusion safety is only about ABO, Rh, and antibody testing โ but sometimes the warning sign is something you can actually see with the naked eye.
Blood components are collected into bags containing anticoagulants to prevent clotting. However, clotting activation can still occasionally occur, leading to the formation of:
- Clots
- Fibrin strands
- Clumps or aggregates
- Abnormal discoloration or appearance
Why is this important?
Because visible clots or fibrin strands may indicate:
- Activation of the coagulation process
- Product quality deterioration
- Improper storage or handling
- Potential risk to the patient if transfused
That is why blood-bank personnel and transfusion services perform careful visual inspection before releasing blood products.
A unit may be rejected even if:
- The blood type is correct
- Compatibility testing is acceptable
- The label appears normal
If unusual findings are seen, the component should be:
- Returned to the transfusion service
- Investigated further
- Withheld from transfusion until deemed safe
Another important laboratory point:
Different blood components can show different abnormal appearances.
For example:
- RBC units can show clots, hemolysis, dark discoloration
- Plasma can show unusual turbidity or color change
- Platelets can show clumping or loss of the normal swirling appearance
This is one of the most fascinating parts of medical laboratory science in transfusion medicine:
Blood-bank safety is not only about compatibility testing โ it also includes visual inspection, storage monitoring, quality control, and product release safety.”
Other posts featuringย Tareq Abadlย onย Hemostasis Today.
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion
-
Jun 6, 2026, 17:37Intissar Haddiya: Can Low-Dose Rivaroxaban Improve Cardiovascular Outcomes in Patients with Advanced CKD?
-
Jun 6, 2026, 17:34Stanley Anokye: From Microcytes and Macrocytes to Target Cells
-
Jun 6, 2026, 16:53Leonardo Roever: Can a Simple Cholesterol Ratio Predict Post-Stroke Depression?
-
Jun 6, 2026, 16:21Abdulkader Jamal Eddin: ABO Blood Group, COVID-19 and Early Respiratory Outcomes in Acute PE
-
Jun 6, 2026, 15:26Yuying Zhang: Grateful to Present on CD44 as A Potential Plasma-Independent Alternative to IVIG in ITP
-
Jun 6, 2026, 15:16Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
-
Jun 6, 2026, 15:14Julianne Chong: Components of Antithrombotic Stewardship Programs from an International Perspective
-
Jun 6, 2026, 15:13Vincent Ten Cate: The Largest Blood-Based EWAS of Atherosclerosis to Date